{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013622","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.988673+00:00","generated_at":"2026-05-15T08:24:28.106786+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Ensysce Biosciences reports Q4 2025 net loss of $2.8M, advances PF614 Phase 3 trial","bullets":["Cash $4.3M at Dec 31, 2025; net loss for 2025 $10.2M vs $8.0M in 2024.","R&D expenses rose $3.2M to $10.4M due to clinical programs for PF614 and PF614-MPAR.","Enrolled first patient in Phase 3 trial (PF614-301) for moderate-to-severe post-surgical pain.","FDA supports streamlined 505(b)(2) pathway for PF614-MPAR with overdose-protection labeling.","USPTO allowed new MPAR patent covering composition-of-matter and method-of-use claims through 2042."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013622","json":"https://secwatch.observer/filing/0001493152-26-013622.json","markdown":"https://secwatch.observer/filing/0001493152-26-013622.md","text":"https://secwatch.observer/filing/0001493152-26-013622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/0001493152-26-013622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:24:28.106786+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}